Treatment Strategy: Why Medicine is the First Choice
At a Glance
For most stable people with renal artery atheroma, intensive medical treatment—blood pressure control, statins, healthy habits, and sometimes aspirin—is preferred over routine stenting; stents may be considered when medicines cannot control dangerous blood pressure or recurrent fluid in the lungs.
For many years, doctors believed that the best way to treat a narrowed renal artery was to “fix” it with a stent. However, major clinical research has changed that perspective. We now know that for the vast majority of stable people, optimal medical therapy (using medications and lifestyle changes) is not just the first step—it is the most effective way to protect your kidneys and your heart [1][2].
The Evidence: Why Medicine Often Wins
Two landmark clinical trials, known as CORAL and ASTRAL, compared patients who received intensive medical treatment to those who received medical treatment plus a stent [2][3].
- The CORAL Trial: Researchers followed nearly 1,000 patients and found that adding a stent did not reduce the risk of heart attack, stroke, or kidney failure compared to medicine alone [2][4].
- The ASTRAL Trial: This study similarly found that stenting did not provide any significant advantage in kidney function, blood pressure control, or survival over long-term follow-up [3].
Because of these findings, medical management is now considered the primary, first-line standard of care for most patients with renal artery atheroma [5].
The Three Pillars of Medical Treatment
Your treatment plan is designed to stabilize the plaque in your artery and prevent the hormonal response that raises your blood pressure.
1. Controlling the RAAS System
As discussed on earlier pages, your kidneys release hormones (the RAAS system) that tighten your blood vessels. Doctors use two main classes of drugs to block this process: ACE inhibitors (like lisinopril) and ARBs (like losartan) [6].
- The Benefit: These are highly effective at lowering blood pressure and protecting the kidneys from long-term damage [1].
- The Monitoring: When you start these drugs, your doctor will check your blood within 1–2 weeks [7]. It is normal for your kidney function (measured by creatinine) to dip slightly at first. However, a significant rise in creatinine (such as 30% or more) can be a sign that the narrowing is very severe, and your doctor may need to adjust your dose [8][6]. Always call your doctor rather than stopping medications on your own.
2. Protecting the Blood Vessels
Because renal artery atheroma is a form of systemic atherosclerosis, you need medications to keep your blood vessels healthy throughout your body.
- Statins: These medications (like atorvastatin) lower your cholesterol, but they also “stabilize” the plaque in your renal artery, making it less likely to grow or rupture [9][2].
- Antiplatelets: A daily low-dose aspirin may be recommended based on your overall cardiovascular and bleeding risk to prevent blood clots from forming on the surface of the plaque. Always ask your clinician before starting [10].
3. Lifestyle: Your Most Powerful Tool
Medication works best when supported by daily habits.
- Smoking Cessation: Smoking is perhaps the greatest risk factor for worsening renal artery disease. People with this condition who smoke tend to develop more severe blockages and experience heart complications at a much younger age [11][2].
- Blood Pressure Targets: While goals are individualized, many guidelines aim for a blood pressure below 130/80 mmHg to prevent further kidney strain [12][1].
- Diabetes and Diet: Managing your blood sugar and reducing salt intake helps take the “pressure” off your kidneys, allowing them to function better even with a limited blood supply [13][14].
When is Medicine Not Enough?
While medicine is the default for stable patients, it is not the only option. Stents are still used, but they are evaluated for specific “high-risk” situations where medications cannot keep the body stable. If your blood pressure remains dangerously high despite multiple medications, or if you experience recurrent fluid in the lungs, your care team may discuss more invasive options, which are covered in the next section [15][1].
Common questions in this guide
Is medicine usually better than a stent for renal artery atheroma?
What medicines are used to treat renal artery atheroma?
Why do I need blood tests after starting an ACE inhibitor or ARB?
When might a renal artery stent be considered?
What lifestyle changes can help protect my kidneys?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How often will I need blood tests to check my creatinine and potassium levels after we adjust my blood pressure medications?
- 2.Based on my overall cardiovascular risk, what is my target blood pressure and LDL cholesterol level?
- 3.Is an ACE inhibitor or an ARB appropriate for my specific type of renal artery narrowing?
- 4.If my kidney function drops slightly after starting a new pill, at what point should we be concerned versus considering it a normal adjustment?
- 5.Are there specific lifestyle changes, like a salt-restricted diet or a particular exercise routine, that you recommend for my situation?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (15)
- 1
Atherosclerotic Renovascular Disease: A KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference.
Hicks CW, Clark TWI, Cooper CJ, et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2022; (79(2)):289-301 doi:10.1053/j.ajkd.2021.06.025.
PMID: 34384806 - 2
Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial.
Tuttle KR, Dworkin LD, Henrich W, et al.
Clinical journal of the American Society of Nephrology : CJASN 2016; (11(7)):1180-1188 doi:10.2215/CJN.10491015.
PMID: 27225988 - 3
Long Term Outcomes After Renal Revascularization for Atherosclerotic Renovascular Disease in the ASTRAL Trial.
O'Keeffe H, Green D, de Bhailis A, et al.
Circulation. Cardiovascular interventions 2024; (17(9)):e013979 doi:10.1161/CIRCINTERVENTIONS.123.013979.
PMID: 39145377 - 4
Relationship of Albuminuria and Renal Artery Stent Outcomes: Results From the CORAL Randomized Clinical Trial (Cardiovascular Outcomes With Renal Artery Lesions).
Murphy TP, Cooper CJ, Pencina KM, et al.
Hypertension (Dallas, Tex. : 1979) 2016; (68(5)):1145-1152 doi:10.1161/HYPERTENSIONAHA.116.07744.
PMID: 27647847 - 5
Atherosclerotic renovascular disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH).
Sarafidis PA, Theodorakopoulou M, Ortiz A, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2023; (38(12)):2835-2850 doi:10.1093/ndt/gfad095.
PMID: 37202218 - 6
Revascularization of atherosclerotic renal artery stenosis in patients with heart failure.
Green D, Cleland JGF, Pellicori P, et al.
European journal of heart failure 2026; doi:10.1093/ejhf/xuag042.
PMID: 41771107 - 7
Pharmacological Effects of RAAS Blockade in Ischemic Nephropathy.
Rivoli L, Di Mario F, Coppolino G, et al.
Current drug metabolism 2016; (17(6)):550-8 doi:10.2174/1389200217666160219114443.
PMID: 26892730 - 8
Secondary Hypertension: Discovering the Underlying Cause.
Charles L, Triscott J, Dobbs B
American family physician 2017; (96(7)):453-461.
PMID: 29094913 - 9
Mortality and Renal Replacement Therapy after Renal Artery Stent Placement for Atherosclerotic Renovascular Disease.
Misra S, Khosla A, Allred J, et al.
Journal of vascular and interventional radiology : JVIR 2016; (27(8)):1215-24.
PMID: 27296703 - 10
Renal artery stenosis.
Safian RD
Progress in cardiovascular diseases 2021; (65()):60-70 doi:10.1016/j.pcad.2021.03.003.
PMID: 33745915 - 11
Cigarette smoking and cardio-renal events in patients with atherosclerotic renal artery stenosis.
Drummond CA, Brewster PS, He W, et al.
PloS one 2017; (12(3)):e0173562 doi:10.1371/journal.pone.0173562.
PMID: 28306749 - 12
Comparative Effectiveness of Management Strategies for Renal Artery Stenosis: An Updated Systematic Review.
Raman G, Adam GP, Halladay CW, et al.
Annals of internal medicine 2016; (165(9)):635-649 doi:10.7326/M16-1053.
PMID: 27536808 - 13
The Maintained Glycemic Target Goal and Renal Function Are Associated with Cardiovascular and Renal Outcomes in Diabetic Patients Following Stent-Supported Angioplasty for Renovascular Atherosclerotic Disease.
Badacz R, Kabłak-Ziembicka A, Rosławiecka A, et al.
Journal of personalized medicine 2022; (12(4)) doi:10.3390/jpm12040537.
PMID: 35455652 - 14
Atherosclerotic-nephropathy: an updated narrative review.
Simeoni M, Borrelli S, Garofalo C, et al.
Journal of nephrology 2021; (34(1)):125-136 doi:10.1007/s40620-020-00733-0.
PMID: 32270411 - 15
This page is for informational purposes only and does not constitute medical advice. Your clinician should tailor medicines, blood pressure targets, and any decision about stenting to your kidney function and overall health.
Get notified when new evidence is published on renal artery atheroma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.